{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:34:58Z","timestamp":1785803698998,"version":"3.56.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"funded by SpliSense LTD"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/17425255.2023.2266361","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T07:23:26Z","timestamp":1696577006000},"page":"709-720","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C-&gt;T mutation, supports a Phase 1\/2 clinical study"],"prefix":"10.1080","volume":"19","author":[{"given":"Lital","family":"Friedman","sequence":"first","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofra-Barchad","family":"Avitzur","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat Ozeri","family":"Galai","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolay","family":"Ferrari","sequence":"additional","affiliation":[{"name":"OnTargetxR&amp;D Inc, Boucherville, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Cohen","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dahan","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Mordechai","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Hart","sequence":"additional","affiliation":[{"name":"SpliSense, BiohouseLabs, Haddasah Ein Kerem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv476"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.07.005"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-013-9495-7"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201207087"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780849387951"},{"issue":"3","key":"e_1_3_7_8_1","first-page":"890","article-title":"Pharmacokinetic properties of 2\u2019-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary RS","year":"2001","unstructured":"Geary RS, Watanabe TA, Truong L, et al. Pharmacokinetic properties of 2\u2019-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther. 2001;296(3):890\u2013897.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101752"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00162-z"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780849387951.ch12"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780849387951.ch11"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250902877680"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.737320"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad067"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1813279"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410133311503"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28523"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400273"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.06.003"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(99)00140-2"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015048419558"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.11.1419"},{"issue":"11","key":"e_1_3_7_24_1","first-page":"1272","article-title":"Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression","volume":"25","author":"Geary RS","year":"1997","unstructured":"Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos. 1997;25(11):1272\u20131281.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.2000.10.359"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji252"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2145"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/08958378.2014.907587"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2008.08.001"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.4.9907078"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07504-1"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2376"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08958370802207318"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-199810050-00001"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02177-9"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1042"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00898-0"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jobcr.2022.04.010"},{"issue":"10","key":"e_1_3_7_39_1","first-page":"1444","article-title":"Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?","volume":"2","author":"Henry SP","year":"2001","unstructured":"Henry SP, Geary RS, Yu R, et al. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Invest Drugs. 2001;2(10):1444\u20131449.","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781420002546.ch9"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/01926230390174995"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.01.008"},{"issue":"5","key":"e_1_3_7_43_1","first-page":"383","article-title":"Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides","volume":"12","author":"Geary RS","year":"1997","unstructured":"Geary RS, Leeds JM, Henry SP, et al. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 1997;12(5):383\u2013393.","journal-title":"Anticancer Drug Des"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10473"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(89)90200-7"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313507003"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"e_1_3_7_48_1","unstructured":"Toxicology review of Advair for NDA 2006."},{"key":"e_1_3_7_49_1","unstructured":"Pharmacology and toxicology of Alvesco review for NDA. 1997."},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctv24q4zdn.23"},{"key":"e_1_3_7_51_1","unstructured":"Pharmacology and toxicology of TOBI review for NDA. 1997."},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2023.0015"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1515\/tnsci-2017-0001"},{"key":"e_1_3_7_54_1","first-page":"8","article-title":"Biogen and ionis pharmaceuticals report nusinersen meets primary endpoint at interim analysis of phase 3 ENDEAR study in infantile-onset spinal muscular atrophy","author":"Nusinersen C","unstructured":"Nusinersen C. Biogen and ionis pharmaceuticals report nusinersen meets primary endpoint at interim analysis of phase 3 ENDEAR study in infantile-onset spinal muscular atrophy. Biog Press Release. Aug 1 2016accessed Jul 5, 2021;8\u201311. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-pharmaceuticals-report-nusinersen-meets-primary","journal-title":"Biog Press Release"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.31525\/cmr-29dc5f3"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2023.2266361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:19:16Z","timestamp":1735294756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2023.2266361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/17425255.2023.2266361"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2023.2266361","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}